Mereo BioPharma Group plc (MREO)
MREO trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1719714/000119312526115226/0001193125-26-115226-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | MREO on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United Kingdom |
| IPO year | Not reported by the screener |
| SEC CIK | 0001719714 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | United Kingdom |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $500K |
| Net income | -$41.9M |
| Operating income | -$40.1M |
| Net margin | -8375.6% |
| Operating margin | -8021.4% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $41.0M |
| Total assets | $45.9M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 97.4× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-09 |
| Cash and burn | $26.1M cash; operating cash flow -$5.5M a quarter. | Report 2026-09-30 |
| Shares outstanding | 159,700,637 (2026-11-09); 159,131,701 a year earlier; 140,257,406 three years earlier. | Cover page 2026-11-09 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | 2 (8-K item 3.01) | 8-K 2026-08-19 |
| Auditor | PricewaterhouseCoopers LLP, Reading, United Kingdom | PCAOB Form AP 2026-04-22 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $800K | -$5.9M | -$4.1M | $26.1M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q2 2026 2026-06-30 | $0 | -$7.0M | -$6.0M | $30.1M | No debt tags | Needs four quarters | 10-Q 2026-08-11 |
| Q1 2026 2026-03-31 | Not filed | -$6.7M | -$4.3M | $30.1M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q4 2025 2025-12-31 | $0 | -$7.4M | -$7.7M | $41.0M | $0 | $500K | 10-K 2026-03-19 |
| Q3 2025 2025-09-30 | $0 | -$7.0M | -$7.3M | $48.7M | $0 | Needs four quarters | 10-Q 2026-11-09 |
| Q2 2025 2025-06-30 | $500K | -$14.6M | -$7.7M | $56.1M | $0 | Needs four quarters | 10-Q 2026-08-11 |
| Q1 2025 2025-03-31 | Not filed | -$12.9M | -$8.3M | $62.5M | $0 | Needs four quarters | 10-Q 2026-11-09 |
| Q4 2024 2024-12-31 | $0 | -$7.0M | -$9.4M | $69.8M | $5.5M | $0 | 10-K 2026-03-19 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2024-12-04 |
| Latest annual report | 10-K | 2026-03-19 |
| Latest quarterly / interim | 10-Q | 2026-11-09 |
| Latest current report | 8-K | 2026-11-09 |
| Latest proxy | DEF 14A | 2026-04-09 |
Source: SEC EDGAR submissions feed, 441 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +8.8% |
| 1 month | -3.7% |
| 3 months | 0.0% |
| Year to date | -26.1% |
| 1 year | -82.7% |
| From 52-week high | -86.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| HOWL | Werewolf Therapeutics Inc. | $0.9908 | +1.07% | $48.2M |
| CTOR | Citius Oncology Inc. | $0.5350 | -6.76% | $49.7M |
| IBIO | iBio Inc. | $0.7067 | -3.42% | $49.8M |
| RFL | Rafael Holdings Inc. | $0.9701 | -9.34% | $50.6M |
| ATNM | Actinium Pharmaceuticals Inc. (Delaware) | $1.49 | -9.15% | $46.8M |
| ANVS | Annovis Bio Inc. | $0.7500 | -19.02% | $46.5M |
| QUCY | Quantum Cyber N.V. | $0.5850 | -7.58% | $51.0M |
| RNXT | RenovoRx Inc. | $0.9549 | -8.18% | $46.1M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier